Page last updated: 2024-12-10
bentiamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 3036235 |
CHEBI ID | 194283 |
SCHEMBL ID | 1231004 |
MeSH ID | M0081102 |
Synonyms (48)
Synonym |
---|
LS-15139 |
bentiamine |
ccris 1339 |
o,s-dibenzoylthiamine |
einecs 206-084-7 |
benzoic acid, thio-, s-ester with n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide benzoate (ester) |
thiamine, o,s-dibenzoyl-, |
bentiaminum [inn-latin] |
dibenzoyl thiamine |
dibenzoylthiamine |
bentiamina [inn-spanish] |
bentiamine [inn] |
o,s-bis(benzoyl)thiamine disulfide |
benzenecarbothioic acid, s-(2-(((4-amino-2-methyl-5-pyrimidinyl)methyl)formylamino)-1-(2-(benzoyloxy)ethyl)-1-propenyl) ester |
n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide o,s-dibenzoate |
D0151 |
299-88-7 |
D09200 |
bentiamine (inn) |
[(z)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-benzoylsulfanylpent-3-enyl] benzoate |
CHEBI:194283 |
[(z)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-ormylamino]-3-benzoylsulanylpent-3-enyl] benzoate |
bentiamina |
unii-8puy50jwlu |
bentiaminum |
8puy50jwlu , |
bentiamine [who-dd] |
o,s-dibenzoyl thiamine |
DTXSID7043827 |
bentiamin |
SCHEMBL1231004 |
n-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-n-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide o,s-dibenzoate |
benzenecarbothioic acid, s-[2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]-1-[2-(benzoyloxy)ethyl]-1-propenyl] ester |
benzoic acid, thio-, s-ester with n-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-n-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide benzoate (ester) |
benzenecarbothioic acid, s-[2-[[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]-1-[2-(benzoyloxy)ethyl]-1-propen-1-yl] ester |
benzoic acid, thio-, s-ester with n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(4-hydroxy-2-mercapto-1-methyl-1-butenyl)formamide benzoate |
thiamine, o,s-dibenzoyl- |
4-[[(4-amino-2-methyl-5-pyrimidinyl)methyl](formyl)amino]-3-(benzoylsulfanyl)-3-pentenyl benzoate # |
AZJUFRDUYTYIHV-NKFKGCMQSA-N |
MLS006011350 |
smr001824965 |
CS-7869 |
4-(n-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido)-3-(benzoylthio)pent-3-en-1-yl benzoate |
AKOS027320992 |
HY-B2212 |
BS-16814 |
Q27270868 |
D81858 |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" In order to compensate thiamine deficiency, several thiamine precursors with higher bioavailability were developed since the 1950s." | ( Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine. Bettendorff, L; Sambon, M; Wins, P, 2021) | 0.62 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
benzoate ester | Esters of benzoic acid or substituted benzoic acids. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (40.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 49.44
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (49.44) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (20.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 3 (60.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |